



Alaska Association of Student Governments

Resolution #5

Continued Funding for the CDMRP's TSCR

Submitted by: Emily Racenet

Submitted: 4/15/2021

Be it Resolved by the Alaska Association of Student Governments that:

- 1. Whereas**, the Congressionally Directed Medical Research Programs (CDMRP), gave \$1.78 billion overall to medical research funding;¹
- 2. Whereas**, since its inception in FY 2002, a total appropriation of \$97 million has been given to the tuberous sclerosis research program (TSCR) from the CDMRP;¹
- 3. Whereas**, TSC is an autosomal dominant genetic disorder causing tumor growth in all major organs of the body and is frequently combined with epilepsy, autism, kidney disease, skin defects, and lung and heart problems;²
- 4. Whereas**, TSC is caused by a mutation on the TSC1 or TSC2 genes, located on the 9th and 16th chromosomes, and causes a cascade of malfunctions on the mTOR signal transduction pathway;²
- 5. Whereas**, the mTOR pathway, normally functioning regulates apoptosis, or regulated cell death, and monitors normal cell growth;³
- 6. Whereas**, when not functioning normally, apoptosis is not carried out properly and cells reproduce rapidly, causing tumor growth;³
- 7. Whereas**, this is the same malfunction that is seen in cancer patients, there is potential that some medications used in TSC patients could be used in cancer patients
- 8. Whereas**, continued funding could lead to additional knowledge on the causes and potential cures of conditions such as cancer, epilepsy, traumatic injury, and

TSC;⁵

9. **Whereas**, it is estimated that 1 in 6,000 children are born with TSC;²

Therefore, be it resolved that the Delegation of AASG supports/opposes continued funding of the TSCRCP during fiscal year 2023.

Action Statement: if passed by the General Assembly of AASG, the resolution will be brought to Congress members to ask for further funding to the TSCRCP.

Sources:

1. “Elucidating the Role of the MTOR Pathway in Tuberous Sclerosis.” 2015 Tuberous Sclerosis Complex Highlight - Elucidating the Role of the mTOR Pathway in Tuberous Sclerosis, Tuberous Sclerosis Complex Research Program, Congressionally Directed Medical Research Programs. Accessed April 12, 2021. https://cdmrp.army.mil/tscrp/research_highlights/15guan_highlight.
2. Hua, Hui, Qingbin Kong, Hongying Zhang, Jiao Wang, Ting Luo, and Yangfu Jiang. “Targeting MTOR for Cancer Therapy.” Journal of Hematology & Oncology. BioMed Central, July 5, 2019. <https://jhoonline.biomedcentral.com/articles/10.1186/s13045-019-0754-1>.
3. “Transforming Healthcare through Innovative and Impactful Research.” Funding History, About Us, Congressionally Directed Medical Research Programs. Accessed April 12, 2021. <https://cdmrp.army.mil/about/fundinghistory>.
4. “Transforming Healthcare through Innovative and Impactful Research.” Tuberous Sclerosis Complex Research Program, Congressionally Directed Medical Research Programs. Accessed April 12, 2021. <https://cdmrp.army.mil/tscrp/default>.
5. “What Is TSC?” TS Alliance, January 11, 2019. <https://www.tsalliance.org/about-tsc/what-is-tsc/>.